<DOC>
	<DOCNO>NCT01017003</DOCNO>
	<brief_summary>This open label , single group , sequential dose study compare single dose pharmacokinetics colchicine 0.6 mg give orally colchicine pharmacokinetics 10 day standard prophylactic dose ( 0.6 mg every 12 hour ) healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetic Study With Colchicine Healthy Volunteers</brief_title>
	<detailed_description>This open label , single group , sequential dose study compare single dose pharmacokinetics colchicine 0.6 mg give orally colchicine pharmacokinetics 10 day standard prophylactic dose ( 0.6 mg every 12 hour ) healthy volunteer . After fast least 10 hour , fourteen healthy non-smoking , non-obese , non-pregnant volunteer receive single oral dose colchicine 0.6 mg. Fasting continue 4 hour dose , time standard meal serve . Blood drawn participant time sufficient adequately define single dose pharmacokinetics colchicine 3 major metabolite , 2 , 3 10 demethylcolchicine . Following 14 day washout period , participant begin 10 day regimen colchicine 0.6 mg orally every 12 hour . On morning day 25 , fast least 10 hour , participant receive final dose colchicine 0.6 mg. Again blood drawn time sufficient determine pharmacokinetics colchicine 3 major metabolite chronic dosing . The pharmacokinetic parameter dose situation derive compare relevant difference . Though specific goal study , participant monitor adverse event observation query period confinement day 1 , 15 25 , well complete blood count ( CBC ) differential clinical chemistry , sit stand blood pressure , heart rate 12-lead electrocardiogram ( EKG ) dosing , day 1 25 .</detailed_description>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Completion screen process within 28 day prior Period I dose Healthy nonsmoking , nonobese adult men woman volunteer age 18 45 year age , weigh least 110 body mass index 1830kg/m2 Women must postmenopausal , surgically sterile , commit abstinence heterosexual sexual contact use two method contraception . Pregnant lactating Use investigational drug within 28 day prior Period I dose . Presence history clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease determine clinical investigator ( ) Positive screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) Clinical laboratory test value outside accept reference range confirm reexamination . Any clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) Use systemic prescription medication 14 day prior Period I dose History allergy ( ) include allergy colchicine relate drug . History drug alcohol addiction abuse within past year positive drug abuse screen Currently recent ( within 6 month ) use tobacco product prior dose administration Donation great 150 mL blood within 28 day plasma within 14 day prior period I dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>healthy</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>